Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin.

  • Authors:
    • G P Stathopoulos
    • S Rigatos
    • N A Malamos
  • View Affiliations

  • Published online on: July 1, 1999     https://doi.org/10.3892/or.6.4.797
  • Pages: 797-1597
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We combined paclitaxel with cis-platin as second-line treatment in patients with non-small cell lung cancer (NSCLC) who had previously undergone first-line therapy with cis-platin combined with cytotoxic drugs other than taxanes. The aim was to evaluate the effect of this cytotoxic combination in patients with refractory tumour to cis-platin. All 36 patients in the study population were evaluable for toxicity and 35 for response. Nine patients were stage IIIa, 15 IIIb and 12 IV. Prior treatment involved cis-platin plus vindesine and epirubicin or vinblastine and mitomycin-C; second-line treatment involved cis-platin (90 mg/m2) and paclitaxel (175 mg/m2), administered once every 3 weeks with 2-6 courses per patient. Partial response (40%) was obtained in 14 patients, 8 of whom had achieved minor response or stable disease after first-line treatment. Response duration was a minimum of 3 months. Toxicity was tolerable; only neurotoxicity was grade II in 16.7% of the patients. On the basis of our results, paclitaxel can be recommended as a very effective cytotoxic drug for NSCLC patients.

Related Articles

Journal Cover

Jul-Aug 1999
Volume 6 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Stathopoulos G, Rigatos S and Malamos N: Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin.. Oncol Rep 6: 797-1597, 1999
APA
Stathopoulos, G., Rigatos, S., & Malamos, N. (1999). Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin.. Oncology Reports, 6, 797-1597. https://doi.org/10.3892/or.6.4.797
MLA
Stathopoulos, G., Rigatos, S., Malamos, N."Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin.". Oncology Reports 6.4 (1999): 797-1597.
Chicago
Stathopoulos, G., Rigatos, S., Malamos, N."Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin.". Oncology Reports 6, no. 4 (1999): 797-1597. https://doi.org/10.3892/or.6.4.797